Sorrento Adds Stem Cell Treatment To Covid-19 Pipeline; Shares Rise, , on October 13, 2020 at 6:51 am

By ILP
On 10/13/2020
In Financial News
Tags:

Shares in Sorrento rose 2.7% in Monday’s extended market session after the company entered into an exclusive license agreement with Personalized Stem Cells (PSC) to buy the global rights to its adipose derived mesenchymal stem cells (MSCs) to treat patients suffering from COVID-19 acute respiratory distress syndrome (ARDS).Sorrento (SRNE) said that the MSC program has been cleared for a Phase 1 clinical trial by the US Food and Drug Administration to the pipeline of COVID-19 focused rescue therapies. As part of the agreement, the company will conduct the Phase 1 trial, which is targeted to enroll about 20 hospitalized COVID-19 patients in California. Pending the results of the Phase 1 trial, Sorrento expects to expand into Phase 2 trials in multiple relevant geographies in consultation with regulatory authorities.Sorrento noted that stem cells have shown to support resolution of symptoms in multiple disease settings and have the potential to reduce the long-term effects associated with pulmonary tissue damage for patients. More specifically, the company believes that stem cells have a high potential to help in the fight against COVID-19 as a stand-alone therapy or in synergy with other product candidates in its pipeline, including small molecules (abivertinib or salicyn-30) and neutralizing antibodies (STI-1499 or STI 2020).“Stem cells were a missing piece in our comprehensive portfolio of potential solutions against COVID-19. We now cover multiple stages of the continuum of care from prevention to potential therapeutic solutions for the most advanced stages of the disease,” said Sorrento CEO Henry Ji. “With PSC’s Phase 1 product candidate, we hope to move quickly through the next clinical trials, and, if successful, be able to provide a supportive therapy that may save the lives of the most advanced patients and may also ensure patients who have to undergo intensive care can benefit from a therapy with the potential to minimize the long-term effects of the disease due to the lung damage created by the virus early in the infection.”The single arm, non-randomized Phase 1 study will evaluate the safety and preliminary efficacy of an adipose-derived allogeneic MSC product candidate. The outcome data will be compared to contemporaneous non-enrolled patients at the same clinical site as the enrolled patients.The primary objective is to test the safety of intravenous infusion of allogeneic adipose stem cells in patients with COVID-19 and in respiratory distress. The secondary objective is to trial a set of safety and efficacy outcome variables to give guidance regarding the risk/benefit ratio in patients with COVID-19 respiratory distress.Sorrento has received two recent Buy ratings from the Street, with Dawson James publishing a $21 price target (84% upside potential) and HC Wainwright setting a more bullish $30 price target (163% upside potential).That’s with shares already up almost 234% year-to-date, boosted by investor optimism for Sorrento’s COVID-19 candidates including its COVI-SHIELD, an antibody cocktail treatment. Dawson James’ Jason Kolbert said he assumes that the company will successfully develop COVI-Shield (and non-opioid Pain Medication, RTX).“We apply a probability of success of just 50%, but given the size of the indication, the valuation potential for COVID alone is significant,” Kolbert wrote in a note to investors. “For Sorrento, we additionally apply a 30% discount rate. Our valuation conclusion is an equally-weighted average of our FCFF, EPS, and sum-of-the-parts analysis rounded to the nearest whole number.” (See SRNE stock analysis on TipRanks).Related News: J&J Halts Covid-19 Vaccine Trial Due To ‘Unexplained Illness’ Opko’s BioReference Lab Begins Covid-19 Testing At NYC Schools Pfizer, BioNTech Initiate Rolling Canada Submission For Covid-19 Vaccine More recent articles from Smarter Analyst: * Nestlé Completes Tender Offer For 84% Stake In Aimmune Therapeutics * New Oriental Rises On Solid Earnings Beat Despite Covid-Headwinds * Altimmune’s COVID-19 Vaccine Shows Positive Results; Street Sees 289% Upside * Sanofi, Regeneron’s Dupixent Significantly Reduces Children’s Asthma Attacks,

Sorrento Adds Stem Cell Treatment To Covid-19 Pipeline; Shares RiseShares in Sorrento rose 2.7% in Monday’s extended market session after the company entered into an exclusive license agreement with Personalized Stem Cells (PSC) to buy the global rights to its adipose derived mesenchymal stem cells (MSCs) to treat patients suffering from COVID-19 acute respiratory distress syndrome (ARDS).Sorrento (SRNE) said that the MSC program has been cleared for a Phase 1 clinical trial by the US Food and Drug Administration to the pipeline of COVID-19 focused rescue therapies. As part of the agreement, the company will conduct the Phase 1 trial, which is targeted to enroll about 20 hospitalized COVID-19 patients in California. Pending the results of the Phase 1 trial, Sorrento expects to expand into Phase 2 trials in multiple relevant geographies in consultation with regulatory authorities.Sorrento noted that stem cells have shown to support resolution of symptoms in multiple disease settings and have the potential to reduce the long-term effects associated with pulmonary tissue damage for patients. More specifically, the company believes that stem cells have a high potential to help in the fight against COVID-19 as a stand-alone therapy or in synergy with other product candidates in its pipeline, including small molecules (abivertinib or salicyn-30) and neutralizing antibodies (STI-1499 or STI 2020).“Stem cells were a missing piece in our comprehensive portfolio of potential solutions against COVID-19. We now cover multiple stages of the continuum of care from prevention to potential therapeutic solutions for the most advanced stages of the disease,” said Sorrento CEO Henry Ji. “With PSC’s Phase 1 product candidate, we hope to move quickly through the next clinical trials, and, if successful, be able to provide a supportive therapy that may save the lives of the most advanced patients and may also ensure patients who have to undergo intensive care can benefit from a therapy with the potential to minimize the long-term effects of the disease due to the lung damage created by the virus early in the infection.”The single arm, non-randomized Phase 1 study will evaluate the safety and preliminary efficacy of an adipose-derived allogeneic MSC product candidate. The outcome data will be compared to contemporaneous non-enrolled patients at the same clinical site as the enrolled patients.The primary objective is to test the safety of intravenous infusion of allogeneic adipose stem cells in patients with COVID-19 and in respiratory distress. The secondary objective is to trial a set of safety and efficacy outcome variables to give guidance regarding the risk/benefit ratio in patients with COVID-19 respiratory distress.Sorrento has received two recent Buy ratings from the Street, with Dawson James publishing a $21 price target (84% upside potential) and HC Wainwright setting a more bullish $30 price target (163% upside potential).That’s with shares already up almost 234% year-to-date, boosted by investor optimism for Sorrento’s COVID-19 candidates including its COVI-SHIELD, an antibody cocktail treatment. Dawson James’ Jason Kolbert said he assumes that the company will successfully develop COVI-Shield (and non-opioid Pain Medication, RTX).“We apply a probability of success of just 50%, but given the size of the indication, the valuation potential for COVID alone is significant,” Kolbert wrote in a note to investors. “For Sorrento, we additionally apply a 30% discount rate. Our valuation conclusion is an equally-weighted average of our FCFF, EPS, and sum-of-the-parts analysis rounded to the nearest whole number.” (See SRNE stock analysis on TipRanks).Related News: J&J Halts Covid-19 Vaccine Trial Due To ‘Unexplained Illness’ Opko’s BioReference Lab Begins Covid-19 Testing At NYC Schools Pfizer, BioNTech Initiate Rolling Canada Submission For Covid-19 Vaccine More recent articles from Smarter Analyst: * Nestlé Completes Tender Offer For 84% Stake In Aimmune Therapeutics * New Oriental Rises On Solid Earnings Beat Despite Covid-Headwinds * Altimmune’s COVID-19 Vaccine Shows Positive Results; Street Sees 289% Upside * Sanofi, Regeneron’s Dupixent Significantly Reduces Children’s Asthma Attacks

,

Contact Us

Please use our Instant Quote form to see if you're pre-qualified for a non-recourse stock loan, or if you have any questions or feedback, please email, call or chat with us.

deals@internationalliquiditypartners.com

+44 20 3994 1588

Headquarters: Hunkins Waterfront Plaza, Charlestown, Nevis

Open 24 hours a day / 7 days a week / 365 days a year

 

 

 

Frequently Asked Questions

What Is Securities-Based Lending?
Securities-based lending, or a stock loan, is the practice of using market investments such as stocks, ETF’s, warrants, bonds, or real estate investment trusts as collateral for a loan.
How much money can I get for my securities?
Borrow up to 80% of the value of your pledged investments giving you the capital you need to expand your business, purchase real estate, or tackle a costly project.
What happens if my securities lose value?
With a non-recourse stock loan, you can walk away from your securities at any time and keep the loan money with no negative credit consequences even if the investments lose value.
Is my information safe with ILP?
We pride ourselves on outstanding service and make client confidentiality our top priority. You can always be absolutely certain your information is safe with us.
How long does it take for the disbursement of funds?
Most of the transactions we process take less than 7 days from application to the disbursement of funds giving you cash quickly when you need it most.
What credit score do I need to qualify?
There are no credit checks or personal guarantees necessary with our services. Your pledged securities are the only collateral required for the loan you receive.

Instant Quote

Please fill out your information to see if you are pre-qualified.

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

International Liquidity Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

International Liquidity Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with International Liquidity Partners, LLC’s internal lending policies. International Liquidity Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Nevis Office

Main Street
Hunkins Waterfront Plaza
Charlestown, Nevis

New York Office

Coming Soon!

Follow Us

Market Coverage